Novartis sales and marketing update

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said an added benefit was not proven for Cosentyx secukinumab vs. comparator therapies to treat psoriatic arthritis or active ankylosing spondylitis (AS). IQWiG said Novartis’ dossier did not include studies comparing Cosentyx with appropriate tumor necrosis factor (TNF) inhibitor therapies. ...